Ziyi Lu Selected Research

Peptides (Polypeptides)

1/2023	Switching from membrane disrupting to membrane crossing, an effective strategy in designing antibacterial polypeptide.
1/2022	Secondary Amine Pendant β-Peptide Polymers Displaying Potent Antibacterial Activity and Promising Therapeutic Potential in Treating MRSA-Induced Wound Infections and Keratitis.
12/2021	Effective and biocompatible antibacterial surfaces via facile synthesis and surface modification of peptide polymers.
5/2019	Practical Preparation of Infection-Resistant Biomedical Surfaces from Antimicrobial β-Peptide Polymers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ziyi Lu Research Topics

Disease

7	Infections 12/2023 - 05/2019
6	Gallbladder Neoplasms (Gallbladder Cancer) 02/2024 - 01/2022
5	Neoplasms (Cancer) 04/2024 - 01/2022
3	Bacterial Infections (Bacterial Infection) 01/2023 - 12/2021
3	Hemolysis 01/2022 - 05/2019
2	Keratitis 01/2022 - 01/2022
1	Autoimmune Diseases (Autoimmune Disease) 04/2024
1	Edema (Dropsy) 04/2024
1	Acute Lung Injury 04/2024
1	Hypoxia (Hypoxemia) 04/2024
1	Pulmonary Hypertension 04/2024
1	Abscess 03/2024
1	Burkitt Lymphoma (Burkitt's Lymphoma) 12/2023
1	Lymphoma (Lymphomas) 12/2023
1	Epstein-Barr Virus Infections 12/2023
1	Pain (Aches) 11/2023
1	Brain Diseases (Brain Disorder) 09/2023
1	Cataract (Cataracts) 01/2023
1	Colitis 01/2023
1	Ulcerative Colitis 01/2023
1	Hepatocellular Carcinoma (Hepatoma) 01/2023
1	Inflammation (Inflammations) 01/2023
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Wound Infection (Wound Infections) 01/2022
1	Invasive Fungal Infections 01/2022

Drug/Important Bio-Agent (IBA)

4	Peptides (Polypeptides)IBA 01/2023 - 05/2019
4	PolymersIBA 01/2022 - 05/2019
2	MicroRNAs (MicroRNA)IBA 04/2024 - 01/2022
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2023 - 01/2022
2	Antimicrobial Cationic PeptidesIBA 01/2022 - 01/2021
1	LipidsIBA 04/2024
1	CytokinesIBA 04/2024
1	baohuoside IIBA 04/2024
1	LipopolysaccharidesIBA 04/2024
1	Competitive Endogenous RNAIBA 04/2024
1	Circular RNAIBA 04/2024
1	fibroblast growth factor 21IBA 04/2024
1	Therapeutic UsesIBA 03/2024
1	Metal-Organic FrameworksIBA 02/2024
1	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2024
1	Antineoplastic Agents (Antineoplastics)IBA 02/2024
1	adavosertibIBA 02/2024
1	DNA (Deoxyribonucleic Acid)IBA 12/2023
1	Tenofovir (Viread)FDA Link 12/2023
1	N- (2- amino- 5- fluorobenzyl)- 4- (N- (pyridine- 3- acrylyl)aminomethyl)benzamideIBA 12/2023
1	Lipoproteins (Lipoprotein)IBA 09/2023
1	rhamnolipidIBA 01/2023
1	Immune Checkpoint InhibitorsIBA 01/2023
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2023
1	Lysine (L-Lysine)FDA Link 01/2023
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	FullerenesIBA 01/2023
1	Penfluridol (Semap)IBA 01/2022
1	Bortezomib (Velcade)FDA Link 01/2022
1	Antifungal AgentsIBA 01/2022
1	AminesIBA 01/2022
1	Biocompatible Materials (Biomaterials)IBA 05/2019

Therapy/Procedure

2	Immunotherapy 04/2024 - 01/2023
2	Therapeutics 09/2023 - 01/2022
1	Drug Therapy (Chemotherapy) 12/2023
1	Injections 11/2023
1	Precision Medicine 09/2023
1	Cutaneous Administration 09/2023
1	Time-to-Treatment 01/2023
1	Oral Administration 01/2023
1	Photochemotherapy (Photodynamic Therapy) 01/2023
1	Phototherapy (Light Therapy) 01/2023
1	Phacoemulsification 01/2023
1	Intravenous Administration 01/2023